much, Thank Chuck. you all. morning, very Good
consciously Biogen in of you morning good course, results is what most interested But of ahead expectations. released where aware we very really a this think of is that I we're going? all too are of set
I put lot particularly an outlined we third And And position in busy quarter. of a grow in indeed, to I months of we've be Biogen was X believe the made the awful would end, year, achieve the a again X that able priorities sustainably. to think say first needed to we to we that To progress. quarter
what to done. To that long has new was treatment really And a all little said patient than product company does our remind and you resources areas a those passionate physicians, outcomes of the that effort. teams were on launches. easier heritage And new We're is a get to our priorities and concerted in very a sclerosis. working move teams multiple and them about to with require focus
products exclusivity want time, The and do is existing for stabilize still have other those significant to we market period a grow thing SPINRAZA. that to of again and VUMERITY notably
to The cost at base. third thing was our really look
address portfolio, to ratios mature resources. sales Although had needed product in peer higher of group, more that. the to our reallocate that, than we and But a we we needed we OpEx our -- one relatively among -- really to had our
to at our development was look for really the pipeline, longer-term Fourth outlook. particularly growth research and
our the have could a have products actually assets any those have And have add on perhaps longer-term practice at think we the target we product probability so those those, of we think I of of which and changed, that success deep most can programs dive fulfilled growth. one terminated looked no that that we promise. where their research has number taken into focus meaningfully a the really to of -- those profile development, We where medicine and changed, longer original had projects
able launch. that in We to at we external said course, look And was always growth. to of zuranolone We the profile, were knew knew And we that been then that a be And even to at launch LEQEMBI nonconventional external wanted interested right launch. we've derisk a to do final that. outset, thing the the the going was launch growth. always we was gradual also
LEQEMBI the antibody But where had mixed So we quarter, at for bag. indication actually major the postpartum as an we anti-amyloid disorder. look course, was disease. important with in on We to first are got of early we receive depression. a Alzheimer's third missed was ZURZUVAE depressive I traditional approval the
is As listing product validating received is and a from be researchers also I that perhaps of and ALS. many many IV to approved the going cause schedule is potential, of neurofilament, treatments of for a find diseases. had genetic necessarily major for you ALS interest and enable DEA, other so from biomarker this to expected, a QALSODY but we revenue the the This we think to treating scientifically, not will milestone further
us As also builds out is we our gives I noted, that But strong SKYCLARYS to growth launch, of we'll that new minute. talk a and Reata opportunity. acquisition in disease about it Pharmaceuticals, off and a whole a closed portfolio. very the rare
the given conditions As the been to to on, we some neurological rare into us trying tended move have we logical risk you and diseases know, has are that go. a adjacencies, focus for of just place to
successful the closer and And launch because needed that, mentioned the I earlier, as structure SPINRAZA, move with we and want we reduction, had same really simplify this more wasn't of but markets of customers. just very empower we organizational about of to Growth the organization think to with we to And Fit SKYCLARYS. more to decision-making do and been cost has the some reinvest Biogen program. the we the can for do
enterprise-wide We and layer have of out an even of organization entire some ended of the in parts up that. organization, the layers taking X
the forward savings cost significant we But change forward. how as to next please? So looking and look we ability do and in to decisions the move share meaningfully we to slide, allocate agility culturally also take I capital I'm those organization. a our per will the Could add to earnings think in
LEQEMBI. in. all you of sure talk very let's about So Subject, are I'm interested
know And always of that guided partly the we're launch. from going have what was also doing. to fundamentals but we experience, gradual We the be that ADUHELM just from this a
is exist of time to needs product administered the treatment networks And process launch. be or that the network. within a at care This did those care a not
to actually quite place, have within clinics of that of in doing the recently and the IDNs So work I significant a Cleveland be announcement they are the while to change to terrific really working clinics. put takes Clinic. time. built, that example these And course, patterns it, a and hard requires think And is by
complexity respected Cleveland that LEQEMBI, patient medical lot that months of ways, know And Clinic of with. they not most And a think with that we're world, We after anywhere their had just the only all they centers the recently first widely and that in dealing I infused commercial to one approval. we're the pioneering in just this science, is we the are approach. speaks the pioneering announced
confidence So What have at we the gives signs We're green us have of we XXX there? number March. we of of an we can getting aim to progress. a course, of think here, get Well, now. shoots patients think end XX,XXX the that of by I
as first things all look intent The of our demand, to are nicely. we extremely patient is, at those treat we internal progress of and seeing metrics
as traditional very to they quickly. the has has provided only the market moved so approval, approval, day actually from EMS traditional patient and of The we not been reimbursement, have relatively use. but hear far registry easy provided what promised, FDA they actually from The
and has confusion that. amyloid some around of had the We CMS clarified PET reimbursement
Now of out I through going to time to the to relieve it's little flow the course, there. But that will that take confusion for also a MAX. down of think some
approval. things most is targeted the I think the we've interesting of one XXX top XX% having of now P&T got IDNs
things patients really for of a meetings lot the wait them meeting. P&T there's the on gives a this of twice being to committees of me able have And and of not the until organized to actually inspiration importance and next year, treatment. but LEQEMBI just meet says is treatment usually, that these a me recognition of that One special a number that get
finally And -- So removing from were CLARITY it amyloid a about that really go evidence benefit. CTAD study compelling until from last at from wasn't there really for remember, have, presented reducing have these year a here, time, the would where clear plaques. of amyloid of was ago benefit the skepticism first we plaque year, the still we whether a really also year here,
was the which the brain. And right going to amount which into patients, to were now, the that's say, go to right, been we've those years, antibodies, tremendous. for right is course, compelling that Well, that's so? has evidence and really to the get antibodies that, -- of "All the we trying that and clear of show gave that that LEQEMBI that first antibody was But can skepticism, rise And why develop And right is one drug occurred. the failed. what was
going. of had Now and to where get this CTAD we done. And And just just don't course, that's about we think fancy. year want what we've we're
more the means generating the for to so data patients. for are comparability demonstrate seen, And to this treatment. we with instance, this the much convenience infusion. work, going treatment subcutaneous We that is that the We've of benefit really have of
a have the the is and this either. How major and XX treatment. is at Others tissue drug But when lot plaque? muscle task we plaque that do no benefit to What mean now come the staying looking tried back? on get months happens brain? a has been into Does through That the have enough We've milestone. you've cleared maintenance shows of you Well, achieved of been dosing. do this. data
actually as we of intriguing of an levels who's actually had lot course And of data that those boxes, and with unexpected early XX% low that with some generated with is those data. over we and early saw patients of discussion patients clinical right stage the fascinating stable measurement, at question We by CTAD. completely the XX% very still are of saw benefit those with awful patients tau. And the sum -- patient? interesting, shown measured CDR Then very the were of
at the Eisai colleague, CEO to in friend So launch LEQEMBI And executing new EU, year filings markets. recent now, of looking and approval got also had of Japan traveling under XX my in China to on I'm we've early Japan. and of other global the Japan, the to in be course, geographic expansion. of review we're We've and the course, with
us internally, we're learn is we've as to green So always to to moment. but every there's And we be launch on see month, And that If this real where going we for have move signs Chuck. But all slide, no track. the something a new. next are said, patient, could please, analogs. is I at one this the
at SPINRAZA something drug. the about in know, look at we XXX same of those, exceeding SKYCLARYS, actually we patients that the about analogs, When all now is And date, on much X,XXX to have all start we're of talk different. including let's forms as Now point with time. you actually known
of we even And waiting there have recall for think cautious, be was we technical been to little a the know case because by because you a months and of number that all the challenge supply. actually approved of more spring, I to product ready that a in was a but physicians. temporary Now that on couple have then due likely delayed may would and patients the
I so was it And think an anticipation.
many strong to a the seeing come, that the speaks so This Nonetheless, lot young world just is their to the available. in and around that life. very been this this that that incredibly of very debilitating desire a there disease is Friedreich's countries approved ataxia. I we're prime think, from ever actually right make to, people first of an for product affects treatment SKYCLARYS has the see And requests understanding is
quarter. that And that. so extremely million benefit had of $XX about it's they in from sales third the We important
are you things is on Well, are I a working we X,XXX start drug? number go things, the and add on why get to to measure need before we XXX this product. genetic value we can there reimbursement, now Biogen tests, on, enzymes on trying of where need One is, that the of liver think is forms the really there and your
physician out is there all the And be to primary of They care not differences well care. do from is in equipped And they're incentives. the Biogen SPINRAZA one that that. could
used are We tests, providing worry we we the provide about those. reimbursement, to genetic don't
patients implants who near We to have mobile to lab help not labs major medical for the we so can get, are done. instance, centers that
how know these through difficult start and the reimbursement situation. to also, And navigate forms we pull
around the think I an medicine this actually I advantage think United there only available States, more for So in important we make getting patients But Biogen can this in the to not to is patients. world. rapidly even
it So with that, I'll to turn Priya. over
